Summitry LLC Buys New Stake in Zoetis Inc. $ZTS

Posted by Brenda Bartman on Aug 1st, 2026

Summitry LLC bought a new position in Zoetis Inc. (NYSE:ZTS – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 179,807 shares of the company’s stock, valued at approximately $21,255,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC acquired a new position in shares of Zoetis in the 1st quarter valued at approximately $10,036,000. Wellington Grp LLC grew its stake in Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock worth $32,000 after buying an additional 267 shares during the last quarter. Liontrust Investment Partners LLP increased its holdings in shares of Zoetis by 5.3% in the 1st quarter. Liontrust Investment Partners LLP now owns 20,935 shares of the company’s stock worth $2,475,000 after acquiring an additional 1,059 shares during the period. Western Wealth Management LLC acquired a new position in shares of Zoetis during the first quarter worth approximately $321,000. Finally, NewEdge Advisors LLC grew its stake in shares of Zoetis by 6.1% in the first quarter. NewEdge Advisors LLC now owns 21,559 shares of the company’s stock worth $2,548,000 after purchasing an additional 1,240 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ZTS shares. Barclays lowered their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Citigroup reduced their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. TD Cowen lowered their target price on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Stifel Nicolaus cut their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Finally, Morgan Stanley decreased their target price on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $118.33.

Check Out Our Latest Report on Zoetis

Insider Buying and Selling

In other news, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 11,650 shares of company stock worth $886,384 in the last 90 days. 0.22% of the stock is owned by company insiders.

Zoetis Trading Up 1.8%

Shares of ZTS stock opened at $77.37 on Friday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The firm’s fifty day simple moving average is $77.05 and its 200 day simple moving average is $102.49. Zoetis Inc. has a 1 year low of $71.47 and a 1 year high of $160.48. The firm has a market capitalization of $32.44 billion, a P/E ratio of 12.83, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75.

Zoetis (NYSE:ZTS – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period last year, the business earned $1.48 earnings per share. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s payout ratio is presently 35.16%.

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.